Venture philanthropy is not just a philosophy. It is a practice and a practice only means something when you can point to the specific decisions it produces.
At Cognigence, our impact investing model begins with a rigorous investment thesis: identify companies at the intersection of technology, healthcare and environmental impact whose work creates measurable social good and has the potential to generate financial returns for our donor-investors. Then back them with capital, provide strategic support and measure outcomes using Harvard SROI.
We have identified and invested in four initial portfolio companies that align with our mission across our focus areas: MedTech, Green Earth and Underprivileged communities. Each one was selected because it addresses a specific gap that government and traditional philanthropy have failed to fill. Each one gives our donors a stake in a solution that matters.
This is what impact investing looks like in practice.
4 portfolio companies across MedTech and Green Earth focus areas Symbio, Vytal, VeraLytics, Qritos | $65T global capital markets, a 1% shift toward impact could close the $2.5T SDG funding gap Cognigence Impact Investment Thesis | 3 core principles: investment with return expectations, range of asset classes, impact measurement Cognigence Approach |
Why Cognigence Invests in Companies, Not Just Causes
Traditional philanthropy funds programs. Cognigence funds solutions. The distinction matters more than it might seem.
A program receives a grant, runs for a year and produces a report. A company builds infrastructure, iterates, scales and, if it succeeds, creates durable change that outlasts any single grant cycle. When Cognigence invests in an early-stage company rather than a program, we are betting that the technology will create systematic, lasting impact rather than isolated, temporary relief.
We are also creating the conditions for financial return. When the companies we back succeed commercially, a portion of the equity upside is returned to the donors whose contributions funded those investments. Charitable giving that gives back; not just emotionally, but financially.
| "We have identified and invested in several initial opportunities that align with our mission and values, that will impact the Global Good and have the opportunity to provide donors with a return beyond their gift." — Cognigence |
Each investment is evaluated against three criteria drawn from Cognigence's impact investment thesis:
Does it generate measurable social or environmental impact?
Does it have the potential to generate a financial return?
Can that return, social and financial, be measured and reported transparently?
The four companies below all met that standard.
Our Portfolio: Four Companies Building the Future
Portfolio Company 1 · MedTech · Healthcare Coordination · Behavioral Health Symbio www.symbiohealth.co |
AI-Powered Real-Time Healthcare Coordination for First Responders and Physicians Symbio provides an advanced cloud-based, AI-driven, HIPAA-compliant platform that puts pertinent real-time patient data at the fingertips of first responders, physicians, 211 organizations and payers, accelerating life-saving outcomes and lowering costs. A unique dimension of Symbio's solution is its specific focus on behavioral health cases in the first responder context, an area that is chronically underserved by existing healthcare IT infrastructure.The Symbio platform reduces costs, improves communication and transparency, strengthens collaboration across the care ecosystem and improves decision support, giving every actor in the chain better information faster. The platform's inclusive architecture is also applicable to global health organizations including the UN, Red Cross and WHO. |
Why Cognigence Invested First responders and emergency physicians are making life-or-death decisions with incomplete data. Behavioral health cases, which account for a significant share of emergency calls, are especially poorly served by fragmented legacy systems. Symbio addresses a specific, measurable gap in healthcare coordination where better technology directly translates to better outcomes and lower system costs. This is a textbook SROI opportunity: investment in coordination infrastructure that prevents expensive downstream interventions. | SROI Opportunity Every life-saving intervention enabled by better data coordination avoids downstream hospitalization costs estimated at $30,000-$100,000 per case. Behavioral health specifically: uncoordinated crisis response costs the US healthcare system over $200 billion annually. Symbio's platform creates measurable value at every touchpoint. |
Portfolio Company 2 · MedTech · Telehealth · Underserved Populations Vytal Health Solutions vytalthsolutions.com |
'Care Anywhere': Bringing Advanced Healthcare to Every Patient, Regardless of Location Vytal's mission is to make Care Anywhere a reality, so that the quality and type of care you receive is not determined by your zip code. Vytal brings care directly to the individual using a combination of artificial intelligence, machine learning, natural language processing and blockchain ledger functionality.Critically, Vytal works within existing healthcare and payer systems to be fully reimbursed, reach underserved demographics and deliver higher patient outcomes, all at a lower cost than traditional care delivery models. This is not a workaround that bypasses the system; it is a platform that makes the system work for everyone, including the populations it currently fails. |
Why Cognigence Invested Geographic inequality in healthcare access is one of the clearest expressions of economic inequality in the United States. Rural communities, low-income urban populations and underserved demographics receive systematically worse care than wealthy, urban populations, not because the medicine is different, but because the delivery system fails them. Vytal directly addresses this gap with technology that extends high-quality care to any patient, anywhere. Its blockchain component also aligns with Cognigence's core transparency infrastructure. | SROI Opportunity Access to quality healthcare is one of the highest-SROI interventions available. Preventable complications from inadequate care access cost the US healthcare system over $100 billion annually. Vytal's Care Anywhere model also directly targets the Medicaid population gap that traditional health VC refuses to fund, producing impact in the communities where Cognigence's investment is most needed. |
Portfolio Company 3 · MedTech · Health Data · Patient Outcomes VeraLytics veralytics.co |
Smart Engagement: A 360° Patient Data Platform That Connects the Entire Care Journey VeraLytics is a Health Gateway company, a specially designed healthcare technology platform that collects extensive patient data from a wide range of disparate sources and devices to provide Smart Engagement: a 360° view of data that enables proactive analysis, real-time communication and improved outcomes.For healthcare stakeholders, VeraLytics delivers across five critical dimensions: care coordination, improved business and administrative processes, increased patient safety and satisfaction, value-based care enablement and costs containment with revenue improvement. In a healthcare system fragmented across dozens of incompatible data sources, VeraLytics builds the connective tissue that allows every actor to see the full patient picture. |
Why Cognigence Invested Healthcare data fragmentation is one of the most expensive structural inefficiencies in the entire US healthcare system, estimated to cost over $30 billion annually in unnecessary tests, duplicated procedures and preventable adverse events. VeraLytics addresses this at the infrastructure level, not the surface level. By providing a true 360° patient data view, it creates the foundation for value-based care, the model proven to deliver better outcomes at lower cost. The SROI of healthcare coordination infrastructure is one of the highest in the sector. | SROI Opportunity Every prevented duplicate test, avoided adverse event and reduced hospital readmission produces measurable cost savings and quality-adjusted life year (QALY) improvements. Value-based care models supported by VeraLytics-style data infrastructure consistently reduce total healthcare costs by 15–25% per patient population, a financial and social return that compounds across every care episode. |
Portfolio Company 4 · Green Earth · Carbon Markets · Climate Technology Qritos qritos.co/ |
The Carbon Credit Market's Trust Problem, Solved With AI and Blockchain Qritos is an AI-driven, blockchain-enabled carbon currency platform transforming the global carbon credit market. It addresses the three critical challenges that have plagued carbon markets since their inception: trust, cost and scale.At the core of Qritos's innovation is advanced blockchain technology, AI-driven data analytics and a scalable platform that validates the quality of carbon credits, ensuring they are real, measurable and reliable financial instruments for investors and stakeholders. Qritos is also minting QOPPA SIGMA, a data-backed, monetizable token that integrates energy efficiency certificates, renewable energy production and peak-shaving initiatives, unlocking both economic and environmental value simultaneously. |
Why Cognigence Invested The carbon credit market is worth over $2 trillion and is projected to grow to $50 trillion by 2050, but it is fundamentally broken by a trust deficit. Carbon credits of dubious quality, double-counted offsets and fraudulent reporting have undermined confidence in the market and reduced its effectiveness as a climate tool. Qritos solves the problem that has stalled the most important market-based climate mechanism available: it makes carbon credits trustworthy, verifiable and scalable. This aligns directly with Cognigence's Green Earth focus area and our blockchain-native infrastructure philosophy. | SROI Opportunity The SROI of high-integrity carbon markets is compounding and global. Every verified carbon credit that Qritos validates represents real emissions avoided, real environmental value created and a real financial instrument that channels capital toward climate solutions. As the market scales to $50 trillion, the impact per dollar of early-stage infrastructure investment becomes exponentially higher, exactly the profile Cognigence's investment thesis targets. |
How Your Donation Connects to These Investments
When you donate to Cognigence, your contribution is pooled with others and deployed through our venture philanthropy model. A portion of that capital funds direct grants to research programs in our focus areas. Another portion is invested in early-stage companies like Symbio, Vytal, VeraLytics and Qritos, companies whose work advances social outcomes in MedTech, healthcare access and climate technology.
Every dollar is tracked on blockchain from the moment of donation to the moment of deployment. You can see exactly whether your contribution went to a grant, an investment, or operational costs, and our $0.25 per dollar overhead ratio means the vast majority reaches the work. Harvard SROI methodology is applied to measure the social value created.
And when these investments succeed, when a portfolio company achieves a clinical milestone, scales its platform, or generates commercial traction, Cognigence's equity gifting model means a portion of that financial upside is returned to the donors who made it possible. Charitable giving that gives back in both senses of the word.
| The companies above were not chosen for their commercial appeal alone. They were chosen because they address specific, measurable gaps in healthcare access, coordination and environmental accountability, gaps that government and pharma have left behind and that philanthropic capital is uniquely positioned to fill. |
This Is What Cognigence's Model Looks Like in Practice
Impact investing is an easy phrase to say. The four companies above are the proof that it means something at Cognigence.
Symbio is improving outcomes for the behavioral health patients that emergency systems fail most often. Vytal is bringing healthcare to the zip codes that traditional delivery ignores. VeraLytics is building the data infrastructure that makes value-based care possible at scale. Qritos is fixing the trust problem that has held back the most important carbon market mechanism available to the climate.
Every one of these is a gap that existed before Cognigence invested. Every one of them maps to a focus area that donors choose when they give. Every one of them has a measurable SROI case. And every one of them represents a donation that does something most charitable gifts cannot: it builds something that lasts.
Your Donation Funds Solutions Like These. When you give through Cognigence, you are not writing a check to a general fund. You are backing companies like Symbio, Vytal, VeraLytics and Qritos, solutions that create measurable, lasting change. Blockchain-verified. Harvard SROI-measured. $0.25 per dollar on operations. Charitable giving that gives back. → See our full investment approach at cognigence.org/approach |
